Susan Shiff

Dr. Shiff joined Merck in 2014 as Senior Vice President and head of the CORE organization. CORE links together epidemiologists, health economists, access and reimbursement scientists, health services researchers and others involved in health policy research with the goal of leading global strategic value evidence generation and access strategy development to optimize reimbursement and patient outcomes across Merck’s portfolio.

Prior to joining Merck, Dr. Shiff was the Global Vice President, Health Economics Research and Evidence Based Medicine at Teva, Inc. Prior to Teva, she spent seven years at Pfizer, including several years as Vice President in the areas of outcomes research, epidemiology, health economics, and access and pricing. She has also led the global risk management group and US HEOR group at Roche and spent four years at the U.S. Centers for Disease Control and Prevention (CDC).

In 2016, Dr. Shiff was named one of the top 15 women in Biopharma by FiercePharma.

Susan received her Ph.D. degree from UCLA, and an MBA degree from Cornell University.

Dr. Shiff currently serves on the Institute for Clinical and Economic Review (ICER), Advisory Board and Methods Sub-Committee; Health Technology Assessment International (HTAi), Policy Advisory Board; the Innovation and Value Initiative (IVI), Panel of Health Advisors, the Academy of Managed Care Pharmacy (AMCP) Foundation Board, and the New Jersey Symphony Orchestra, Board of Trustees, Education, and Development Committees. Dr. Shiff is also a Non-Executive Director of Synthace Ltd and a voting member of the Merck Global Health Innovation Fund, LLC, Innovation Venture Board.